Rusfertide
Polycythemia Vera
NDA SubmittedActive (Priority Review)
Key Facts
Indication
Polycythemia Vera
Phase
NDA Submitted
Status
Active (Priority Review)
Company
About Takeda Pharmaceutical
Takeda Pharmaceutical is a purpose-driven, global biopharmaceutical leader with a mission to create better health for people and a brighter future for the world. Its strategy is built on a balanced, diverse portfolio across five core therapeutic areas and a commitment to translating advanced science into life-transforming treatments. The company's 2019 acquisition of Shire plc was a pivotal event, establishing its leadership in rare diseases and significantly expanding its global footprint. Takeda is now executing a transformation to strengthen competitiveness and accelerate future growth, focusing on innovation, operational excellence, and sustainability.
View full company profileTherapeutic Areas
Other Polycythemia Vera Drugs
| Drug | Company | Phase |
|---|---|---|
| Jakafi (ruxolitinib) | Incyte | Marketed |
| Rusfertide (PTG-300) | Protagonist Therapeutics | Phase 3 |
| DISC-3405 | Disc Medicine | Phase 2b |